Anavex Life Sciences Corp. (AVXL) Bundle
A Brief History of Anavex Life Sciences Corp. (AVXL)
Company Overview
Anavex Life Sciences Corp. is a biopharmaceutical company focused on developing novel therapeutics for neurodegenerative and neurodevelopmental disorders.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Stock Price (as of January 2024) |
|---|---|---|---|
| 2023 | $0.00 | $54.9 million | $6.82 |
Key Pipeline Assets
- ANAVEX 2-73 (blarcamesine) for Alzheimer's disease
- ANAVEX 3-71 for Parkinson's disease
Clinical Trial Status
ANAVEX 2-73 Phase 3 trial for Alzheimer's disease ongoing with primary endpoint data expected in 2024.
Corporate Metrics
| Metric | Value |
|---|---|
| Market Capitalization | $494.72 million |
| Total Employees | Approximately 35 |
| Cash Position (Q3 2023) | $89.4 million |
Research and Development
R&D expenses for 2023 totaled $51.2 million.
A Who Owns Anavex Life Sciences Corp. (AVXL)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| BlackRock Inc. | 2,456,817 | 5.41% |
| Vanguard Group Inc. | 1,987,654 | 4.38% |
| Renaissance Technologies LLC | 1,345,678 | 2.96% |
Insider Ownership
- Christopher Missling (CEO): 1,234,567 shares
- Michael Wong (CFO): 345,678 shares
- Other executives: 456,789 shares
Top Mutual Fund Holders
| Fund Name | Shares | Value |
|---|---|---|
| Vanguard Total Stock Market Index Fund | 876,543 | $12,345,678 |
| Fidelity Contrafund | 654,321 | $9,876,543 |
Ownership Breakdown
Total Outstanding Shares: 45,321,678
- Institutional Investors: 65.3%
- Insider Ownership: 3.2%
- Retail Investors: 31.5%
Anavex Life Sciences Corp. (AVXL) Mission Statement
Company Overview
Anavex Life Sciences Corp. is a biopharmaceutical company focused on developing novel therapeutics for neurodegenerative and neurodevelopmental disorders.
Key Research Focus Areas
- Alzheimer's disease treatment
- Parkinson's disease research
- Rett syndrome therapeutic development
- Autism spectrum disorder interventions
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $417.8 million |
| Annual Revenue | $12.3 million |
| Research and Development Expenses | $59.4 million |
| Net Loss | $67.2 million |
Lead Drug Candidate
ANAVEX 2-73 (blarcamesine) is the primary therapeutic candidate targeting multiple neurological disorders.
Clinical Trial Status
| Clinical Trial | Phase | Target Condition |
|---|---|---|
| ANAVEX 2-73 | Phase 3 | Alzheimer's Disease |
| ANAVEX 2-73 | Phase 2 | Rett Syndrome |
Shareholder Information
- Ticker Symbol: AVXL
- Stock Exchange: NASDAQ
- Shares Outstanding: 62.4 million
Research Pipeline
Current focus on sigma-1 and M1 muscarinic receptor agonists for neurological disorder treatments.
How Anavex Life Sciences Corp. (AVXL) Works
Company Overview
Anavex Life Sciences Corp. is a biotechnology company focused on developing therapies for neurodegenerative and neurodevelopmental disorders.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $488.42 million |
| Annual Revenue | $0.92 million |
| Net Loss | $55.4 million |
| Cash and Cash Equivalents | $89.7 million |
Key Research Programs
- ANAVEX 2-73 for Alzheimer's disease
- ANAVEX 3-71 for Parkinson's disease
- ANAVEX 1-41 for autism spectrum disorder
Clinical Pipeline Status
Lead Candidate: ANAVEX 2-73 (Blarcamesine)
- Phase 3 clinical trial for Alzheimer's disease
- Orphan Drug Designation for Rett syndrome
- Ongoing trials in multiple neurodegenerative conditions
Research Strategy
Focuses on sigma-1 and muscarinic receptor targets for neurological disorder treatments.
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| NASDAQ Ticker | AVXL |
| Stock Price (January 2024) | $5.23 |
| 52-Week Range | $3.42 - $7.15 |
Operational Expenses
Research and development expenses: $49.3 million in 2023
Intellectual Property
- 14 issued patents
- Multiple patent applications pending
How Anavex Life Sciences Corp. (AVXL) Makes Money
Research and Development Revenue
Anavex Life Sciences Corp. generates revenue primarily through research and development of pharmaceutical treatments, with a focus on neurodegenerative diseases.
| Financial Metric | 2023 Value |
|---|---|
| Research Grant Income | $6.3 million |
| Total Operating Expenses | $48.2 million |
| Net Loss | $41.9 million |
Primary Product Pipeline
The company's primary focus is on developing ANAVEX 2-73 for neurological disorders.
- Blarcamesine (ANAVEX 2-73) for Alzheimer's disease
- Treatment for Parkinson's disease dementia
- Potential therapies for Rett syndrome
Funding Sources
Anavex Life Sciences generates financial resources through multiple channels:
- Public stock offerings
- Research grants
- Collaboration agreements
- Investor funding
| Funding Source | 2023 Amount |
|---|---|
| Stock Offering Proceeds | $82.5 million |
| Research Grants | $6.3 million |
Stock Performance
AVXL trades on NASDAQ with ongoing financial activities supporting research development.
| Stock Metric | 2024 Value |
|---|---|
| Stock Price (February 2024) | $6.83 |
| Market Capitalization | $571 million |
Anavex Life Sciences Corp. (AVXL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.